He-Liang Wu
Overview
Explore the profile of He-Liang Wu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
19
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liang X, Su Y, Li X, Fu Y, Ma R, Yang R, et al.
Ann Surg Oncol
. 2024 Nov;
32(4):2912-2922.
PMID: 39538101
Objectives: This study was designed to explore the survival benefit factors of malignant peritoneal mesothelioma (MPM) patients after cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) and to make dynamic...
2.
Liang X, Su Y, Fu Y, Li X, Ma R, Yang R, et al.
Eur J Surg Oncol
. 2024 Sep;
50(11):108692.
PMID: 39298871
Background: The comprehensive treatment strategy, mainly cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC), combined with systemic and intraperitoneal chemotherapy, is the standard treatment for malignant peritoneal mesothelioma (MPM), which...
3.
Su Y, Ma R, Fu Y, Wu H, Liang X, Liu Y, et al.
J Surg Oncol
. 2024 Aug;
130(6):1225-1234.
PMID: 39183488
Background: To explore the most effective adjuvant chemotherapy regimen for malignant peritoneal mesothelioma (MPM) through patient derived tumor-like cell clusters (PTC) drug sensitivity test. Methods: PTC were cultured in vitro...
4.
Liu Y, Wu H, Su Y, Wang Y, Li Y
Cancer Biother Radiopharm
. 2024 Aug;
39(8):551-561.
PMID: 39093850
Malignant peritoneal mesothelioma (MPeM) is a rare primary malignant tumor originating from peritoneal mesothelial cells. Insufficient specificity of the symptoms and their frequent reappearance following surgery make it challenging to...
5.
Liang X, Li X, Fu Y, Su Y, Ma R, Yang R, et al.
J Surg Oncol
. 2024 Jul;
130(3):533-542.
PMID: 39082465
Malignant peritoneal mesothelioma (MPM) is a rare and invasive tumor, and some patients will develop paraneoplastic syndrome (PS) during the course of the disease. This review summarizes PS associated with...
6.
Liang X, Su Y, Li X, Fu Y, Ma R, Yang R, et al.
World J Surg Oncol
. 2024 Jan;
22(1):29.
PMID: 38267958
Background: Malignant peritoneal mesothelioma (MPM) is a rare and highly aggressive tumor. Its clinical manifestations are diverse, and the symptoms are not specific. Some patients will develop paraneoplastic syndrome (PS)...
7.
Yang R, Fu Y, Li X, Ma R, Su Y, Wu H, et al.
World J Surg Oncol
. 2023 Oct;
21(1):347.
PMID: 37891655
Background: As the standard treatment for pseudomyxoma peritonei (PMP), cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) can significantly prolong the survival of PMP patients, and some patients can even...
8.
Lin Y, Zhu J, Ma R, Meng W, Wang Z, Li X, et al.
Mol Cancer Res
. 2023 Sep;
22(1):70-81.
PMID: 37768171
Implications: This work describes exhaustive mutation profile of PMP based on WES data and derives ten mutation signatures, which divides patients into two clusters and serve as an independent prognostic...
9.
Yang R, Zhao X, Fu Y, Lin Y, Ma R, Su Y, et al.
BMC Cancer
. 2023 Sep;
23(1):903.
PMID: 37752468
Background: Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) is the standard treatment for pseudomyxoma peritonei (PMP). It can significantly prolong the survival of patients, but at the same time...
10.
Su Y, Zhao X, Ma R, Fu Y, Yang Z, Wu H, et al.
Int J Hyperthermia
. 2023 Jun;
40(1):2223374.
PMID: 37348853
Objectives: To establish a Bayesian network (BN) model to predict the survival of patients with malignant peritoneal mesothelioma (MPM) treated with cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC). Methods:...